Trial record 2 of 12 for:
GSK1120212+GSK2141795 for Cervical Cancer
This study is currently recruiting participants.
Verified February 2014 by Dana-Farber Cancer Institute
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute
First received: October 4, 2013
Last updated: February 6, 2014
Last verified: February 2014
This research study is evaluating the combination of two drugs called GSK1120212 (trametinib) and GSK2141795 as a possible treatment for recurrent or persistent cervical cancer. Trametinib and GSK2141795 are drugs that may stop cancer cells from growing. Trametinib is a MEK inhibitor - it blocks a protein called MEK that is commonly overactive in tumor cells. GSK2141795 is an AKT inhibitor which blocks a pathway in cancer cells that is commonly overactive in tumor cells called the PI3kinase pathway. In this research study, the investigator is looking to see whether the combination of Trametinib and GSK2141795 is useful in treating recurrent and persistent cervical cancer.
Additionally, the investigator is looking to see if participants whose tumors contain a particular genetic make-up will have better response to combination trametinib and GSK2141795. Participants' tumors will be tested for mutations in genes which could make some cancers more susceptible to trametinib and GSK2141795.
Drug: GSK1120212 (trametinib)
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer
Primary Outcome Measures:
Secondary Outcome Measures:
- Duration of progression-free (PFS) [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
The duration of progression-free (PFS) following initiation of therapy with GSK1120212 (trametinib) and GSK2141795 will be measured.
- Toxicity of GSK1120212 (trametinib) and GSK2141795. [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
Toxicity will be assessed for this combination by version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) in this cohort of patients.
- Mutation and co-mutation rates of genes in the PI3K and RAS ERK signaling pathways in recurrent cervical cancer using high throughput targeted mutational analysis on participant tumor samples. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
The mutation and co-mutation rates of genes in the PI3K and RAS ERK signaling pathways in recurrent cervical cancer will be interrogated using high throughput targeted mutational analysis on participant tumor samples.
- Association of mutational status with clinical benefit from GSK1120212 (trametinib) and GSK2141795. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
The association of mutational status along with clinical benefit from GSK1120212 (trametinib) and GSK2141795 will be explored in this study.
- Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Overall survival will be determined for subjects on this study
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||July 2016 (Final data collection date for primary outcome measure)
Experimental: GSK1120212 (trametinib) and GSK2141795
GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
Drug: GSK1120212 (trametinib)
Trametinib dose is 1.5 mg orally once per day
Other Name: Trametinib
The dose of GSK2141795 is 50 mg orally once per day
Other Name: GSK2141795
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Recurrent or metastatic cervical cancer of any histology
- Measurable disease by RECIST 1.1.
- Prior Therapy:
- At least one prior chemotherapy regimen for management of cervical cancer. Radiation-sensitizing chemotherapy will not be counted as a systemic chemotherapy regimen
- Patients can have received one additional regimen for treatment
- No prior receipt of PI3K or RAS-ERK pathway inhibitors
- Age ≥ 18 years
- Life expectancy > 3 mos
- ECOG performance status ≤ 2
- Participants must have normal organ function as defined below:
- Absolute Neutrophil Count (ANC)≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin > 9.0/dL
- AST (SGOT) and ALT (SGPT) ≤ 2.5 × institutional ULN
- Total Bilirubin within normal institutional limits
- Albumin ≥ 2.5 g/dL
- Creatinine ≤ upper limit of institutional normal or creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal or ≥ 50 mL/min 24-hour creatinine clearance
- Normal LVEF
- Normal fasting Blood Glucose
- Availability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue
- Normal blood pressure (systolic < 140 mmHg and diastolic < 90 mmHg)
- Women of childbearing potential must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
- Toxicities of prior therapy (excepting alopecia) should be resolved to ≤ grade 1
- Ability to tolerate oral medications and no malabsorption
- Ability to sign an informed consent
- No previous chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C,) or radiation therapy within 2 weeks prior to entering the study
- No use of investigational agents nor have participated in an investigational trial within the past 4 weeks (or five half-lives whichever is shorter; with a minimum of 14 days from the last dose).
- Presence of active GI disease that could affect GI absorption or predispose a subject to GI ulceration.
- Evidence of mucosal of internal bleeding
- Major surgery within the last 4 weeks
- No Type 1 diabetes; however, patients with Type 2 diabetes are eligible if diagnosed ≥ 6 months prior to enrollment and if hemoglobin A1C (HbA1C) ≤ 8% at screening.
- Symptomatic or unstable brain metastases or asymptomatic and untreated but > 1 cm in the longest dimension
- Symptomatic or untreated leptomeningeal or spinal cord compression.
- Individuals with a history of a different malignancy are ineligible except for the following circumstances: the following cancers are eligible if diagnosed and treated within the past 3 years: breast cancer in situ and basal cell or squamous cell carcinoma of the skin, stage I colon carcinoma confined to a polyp.
- Any serious and/or unstable pre-existing medical disorders
- Known infection with HIV, Hepatitis B Virus, or Hepatitis C Virus
- Chronic use of drugs that are strong inhibitors or inducers of p450 CYP3A4
- known immediate or delayed hypersensitivity reaction or idiosyncrasy to study drugs
- History of interstitial lung disease or pneumonitis.
- Presence of cardiac metastases
- Subject with intra-cardiac defibrillators or pacemaker.
- History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
- History of RVO or CSR, or predisposing factors to RVO or CSR
- Visible retinal pathology as assessed by ophthalmic exam
- History or evidence of cardiovascular risk including any of the following
- QTcF≥ 480 msec ( ≥ 500 msec for subject with bundle branch block)
- History or evidence of current clinically significant uncontrolled arrhythmias. (Exception: controlled atrial fibrillation for >30 days prior to randomization)
- History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months of study entry.
- Class II or higher congestive heart failure.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01958112
|Dana-Farber Cancer Institute
|Boston, Massachusetts, United States, 02215 |
|Contact: Christin Whalen, RN 617-582-7738 firstname.lastname@example.org |
|Contact: Kristen Savoie 617-632-3346 email@example.com |
|Principal Investigator: Ursula Matulonis, MD |
Dana-Farber Cancer Institute
National Comprehensive Cancer Network
||Ursula A. Matulonis, MD
||Dana-Farber Cancer Institute
No publications provided
||Ursula A. Matulonis, MD, Principal Investigator, Dana-Farber Cancer Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 4, 2013
||February 6, 2014
||United States: Institutional Review Board
United States: Food and Drug Administration
Keywords provided by Dana-Farber Cancer Institute:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 17, 2014
Uterine Cervical Neoplasms
Genital Neoplasms, Female
Neoplasms by Site
Uterine Cervical Diseases
Genital Diseases, Female